Document:

Exhibit 4.5

AMENDMENT NO. 4 TO RIGHTS AGREEMENT

 

This Amendment No. 4 (this “Amendment”)
dated the 11th day of March, 2022 to the Rights Agreement, dated March 11, 2018, as amended by Amendment No. 1 thereto, dated March 8,
2019, as further amended by Amendment No. 2 thereto, dated March 10, 2020 and Amendment No. 3 thereto, dated March 8, 2021 (the “Agreement”),
by and between Heat Biologics, Inc. (the “Company”) and Continental Stock Transfer & Trust Company, as Rights Agent
(the “Rights Agent”).  Capitalized terms used herein without definition shall have the meanings assigned in the
Agreement.  

 

WHEREAS, pursuant to Section
27 of the Agreement, the Company and the Rights Agent may, for so long as the Rights are redeemable, from time to time, change or supplement
the provisions under the Rights Agreement as the Company may deem necessary or desirable, without the approval of any holders of the Rights;

 

WHEREAS, as of the date hereof,
a Flip-In Event has not occurred and, as such, the Rights are presently redeemable;

 

WHEREAS, the Company desires
to amend the Agreement to extend the final expiration date of the Rights from the Close of Business on March 11, 2022 to the Close of
Business on March 11, 2023; and

 

WHEREAS, pursuant to Section
27 of the Agreement, the Company hereby directs the Rights Agent that the Rights Agreement shall be amended as set forth in this Amendment.

 

NOW THEREFORE, the Company
and the Rights Agent agree to amend the Agreement as follows:

 

1.      
Section 7(a) of the Agreement is hereby amended and restated in its entirety to read as follows:

 

“Except as otherwise provided
herein, the Rights shall become exercisable on the Distribution Date, and thereafter the registered holder of any Right Certificate (other
than Right Certificates representing Rights that have become void pursuant to Section 11(a)(ii) hereof or that have been exchanged pursuant
to Section 24 hereof) may, subject to Section 11(a)(ii) hereof and except as otherwise provided herein, exercise the Rights evidenced
thereby in whole or in part upon surrender of the Right Certificate, with the form of election to purchase on the reverse side thereof
duly executed, to the Rights Agent at the office or agency of the Rights Agent designated for such purpose, together with payment of the
aggregate Purchase Price with respect to the total number of shares of Common Stock (or other securities, cash or other assets, as the
case may be) as to which the Rights are exercised, at any time which is both after the Distribution Date and prior to the time (the “Expiration
Date”) that is the earliest of (i) the Close of Business on March 11, 2023, (ii) the time at which the Rights are redeemed as provided
in Section 23 hereof (the “Redemption Date”), (iii) the closing of any merger or other acquisition transaction involving the
Company pursuant to an agreement of the type described in Sections 1(d)(ii)(A)(z) and 13(f) at which time the Rights are terminated, or
(iv) the time at which such Rights are exchanged as provided in Section 24 hereof.”

 

		2.	The Form of Rights Certificate attached as Exhibit A to the Agreement and the Summary
of Rights to Purchase Shares of Common Stock of Heat Biologics, Inc. attached as Exhibit B to the Agreement are each
amended to replace each reference to “March 11, 2022” contained therein with “March 11, 2023”.

 

		3.	This Amendment shall be effective immediately as of the date first written above, and thereafter, all
references to the Agreement shall be deemed to be references to the Agreement, as amended hereby.

 

		4.	All other terms of the Agreement shall remain in full force and effect.

 

    	 

    	 

    

 

 

		5.	The undersigned officer of the Company hereby certifies to the Rights Agent that the amendments to the
Agreement set forth in this Amendment are in compliance with Section 27 of the Rights Agreement and the certification contained in this
Section 7 shall constitute the certification required by Section 27 of the Agreement.

 

 

 

[Signature page follows]

 

    	 

    	 

    

 

IN WITNESS WHEREOF, the parties
hereto have caused this Agreement to be duly executed as of the day and year first above written.

 

	 	 	 
	 	 	 
	 	HEAT BIOLOGICS, INC.
	 	 	 
	 	 	 
	 	 	 
	 	By:	/s/ Jeffrey Wolf
	 	Name:	Jeffrey Wolf
	 	Title:	President and Chief Executive Officer
	 	 	 
	 	 	 
	 	 	 
	 	CONTINENTAL STOCK TRANSFER & TRUST COMPANY, as Rights Agent
	 	 	 
	 	 	 
	 	 	 
	 	By:	/s/ Stacy Aqui
	 	Name:	Stacy Aqui
	 	Title:	Vice Presidentgraham_john-dbol

257043017 v2          November 23, 2021  John Graham  VIA EMAIL/DOCUSIGN  Dear John,  You are currently employed as Chief Marketing Officer of DB Management Co. (the “Company”),  wholly-owned subsidiary of Dutch Mafia, LLC.  This letter sets forth the terms and conditions of your  employment by the Company, including the provision of services to Dutch Mafia, LLC and its affiliated  entities, including Dutch Bros Inc, with such terms to be effective as of November 1, 2021.  The terms  set forth in this letter agreement shall supersede and replace, in entirety, the terms set forth in your offer  letter dated July 10, 2020.  1. POSITION. You are serving in a full-time capacity as Chief Marketing Officer of the Company  and Dutch Bros Inc.  In this role, you report to the Chief Executive Officer.  You are currently  working out of Florida.  Subject to the other provisions of this letter agreement, we may change  your position, duties, and work location from time to time at our discretion.  2. EMPLOYEE BENEFITS. As a regular employee of the Company, you are eligible to participate  in the Company’s standard benefits, subject to the terms and conditions of such plans and  programs. Subject to the other provisions of this letter agreement, we may change compensation  and benefits from time to time at our discretion.  3. SALARY. Your annual base salary is $500,000, less deductions and withholdings, payable in  semi-monthly installments in accordance with the Company’s standard payroll practices for  salaried employees. This salary will be subject to adjustment pursuant to the Company’s  employee compensation policies in effect from time to time.  4. BONUS. You are eligible for annual incentive bonus compensation equal to $250,000.  Your  bonus will be paid to you in the form of equal semi-monthly payments, subject to deductions and  withholdings.  5. EQUITY.  You have been granted various equity interests in Dutch Bros. Inc.  Those equity  interests shall continue to be governed in all respects by the terms of the applicable equity  agreements, grant notices and equity plans.    6. PROPRIETARY INFORMATION AND INVENTIONS AGREEMENT. You are required, as a  condition of your continuing employment, to execute the Employee Confidential Information  and Inventions Assignment Agreement attached hereto as Exhibit A.  7. PERIOD OF EMPLOYMENT. Your employment remains “at will,” meaning that either you or  the Company (or any of its affiliated entities) may terminate your employment at any time and  for any reason, with or without cause.  This remains the full and complete agreement between  you and the Company (and any of its affiliated entities) on this term. Although your job duties,  title, compensation and benefits, as well as the Company’s personnel policies and procedures,  DocuSign Envelope ID: 91092997-88D2-42A9-922E-23A75D16417F 

 

257043017 v2        may change from time to time, the “at will” nature of your employment may only be changed in  an express written agreement signed by you and a duly authorized member of the Board of  Directors of Dutch Bros Inc.  8. SEVERANCE.  You will be eligible for severance benefits under the terms and conditions of the  Dutch Bros Inc. Amended and Restated Severance and Change in Control Plan.  9. AMENDMENT. This letter agreement (except for terms reserved to the Company’s discretion)  may not be amended or modified except by an express written agreement signed by you and a  duly member of the Board of Directors of Dutch Bros Inc.  10. ARBITRATION. To ensure the rapid and economical resolution of disputes that may arise in  connection with your employment with the Company or the services you provide to the  Company’s affiliated entities, you and the Company (together with all of its affiliated entities)  agree that any and all disputes, claims, or causes of action, in law or equity, including but not  limited to statutory claims, arising from or relating to the enforcement, breach, performance, or  interpretation of this agreement, your employment with the Company or the services you provide  to the Company’s affiliated entities, or the termination of your employment, shall be resolved  pursuant to the Federal Arbitration Act, 9 U.S.C. § 1-16, to the fullest extent permitted by law,  by final, binding and confidential arbitration conducted by JAMS or its successor, under JAMS’  then applicable rules and procedures for employment disputes before a single arbitrator  (available upon request and also currently available at http://www.jamsadr.com/rules- employment-arbitration/). You acknowledge that by agreeing to this arbitration procedure,  both you and the Company waive the right to resolve any such dispute through a trial by  jury or judge or administrative proceeding.  In addition, all claims, disputes, or causes of  action under this section, whether by you or the Company, must be brought in an individual  capacity, and shall not be brought as a plaintiff (or claimant) or class member in any purported  class or representative proceeding, nor joined or consolidated with the claims of any other person  or entity.  The arbitrator may not consolidate the claims of more than one person or entity, and  may not preside over any form of representative or class proceeding.  To the extent that the  preceding sentences regarding class claims or proceedings are found to violate applicable law or  are otherwise found unenforceable, any claim(s) alleged or brought on behalf of a class shall  proceed in a court of law rather than by arbitration.  This paragraph shall not apply to any action  or claim that cannot be subject to mandatory arbitration as a matter of law (collectively, the  “Excluded Claims”).  In the event you intend to bring multiple claims, including one of the  Excluded Claims listed above, the Excluded Claims may be filed with a court, while any other  claims will remain subject to mandatory arbitration.  You will have the right to be represented by  legal counsel at any arbitration proceeding. Questions of whether a claim is subject to arbitration  under this agreement shall be decided by the arbitrator.  Likewise, procedural questions which  grow out of the dispute and bear on the final disposition are also matters for the arbitrator.  The  arbitrator shall: (a) have the authority to compel adequate discovery for the resolution of the  dispute and to award such relief as would otherwise be permitted by law; and (b) issue a written  statement signed by the arbitrator regarding the disposition of each claim and the relief, if any,  awarded as to each claim, the reasons for the award, and the arbitrator’s essential findings and  conclusions on which the award is based. The arbitrator shall be authorized to award all relief  that you or the Company would be entitled to seek in a court of law. The Company shall pay all  JAMS arbitration fees in excess of the administrative fees that you would be required to pay if  DocuSign Envelope ID: 91092997-88D2-42A9-922E-23A75D16417F 

 

257043017 v2        the dispute were decided in a court of law. Nothing in this letter agreement is intended to prevent  either you or the Company from obtaining injunctive relief in court to prevent irreparable harm  pending the conclusion of any such arbitration.  Any awards or orders in such arbitrations may  be entered and enforced as judgments in the federal and state courts of any competent  jurisdiction.  * * *  This letter, together with your Employee Confidential Information and Inventions Assignment  Agreement, equity agreements and other agreements referenced herein, forms the complete and  exclusive statement of your employment agreement with the Company and its affiliated entities, and  supersedes any other agreements or promises made to you by anyone, whether oral or written, with  respect to the subject matter hereof. If any provision of this offer letter agreement is determined to be  invalid or unenforceable, in whole or in part, this determination shall not affect any other provision of  this offer letter agreement and the provision in question shall be modified so as to be rendered  enforceable in a manner consistent with the intent of the parties insofar as possible under applicable law.   This letter may be delivered and executed via facsimile, electronic mail (including pdf or any electronic  signature complying with the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act or  other applicable law) or other transmission method and shall be deemed to have been duly and validly  delivered and executed and be valid and effective for all purposes.  Please sign and date this letter below to indicate your agreement with its terms.    Sincerely,      Jonathan Ricci, Chief Executive Officer  ACCEPTED AND AGREED TO:       John Graham    Dated:  __________________________        DocuSign Envelope ID: 91092997-88D2-42A9-922E-23A75D16417F 11/29/2021 | 8:13 AM PST

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00341-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00341-of-00352.parquet"}]]